A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Am J Hematol. 2019 Dec;94(12):E319-E322. doi: 10.1002/ajh.25633. Epub 2019 Oct 4.

Authors

Affiliations

¹ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Karyopharm Therapeutics, Newton, Massachusetts.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁴ Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

PMID: 31489991
DOI: 10.1002/ajh.25633

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Dexamethasone / administration & dosage
Dexamethasone / adverse effects
Drug Resistance, Neoplasm
Female
Humans
Lenalidomide / administration & dosage
Lenalidomide / adverse effects
Male
Maximum Tolerated Dose
Middle Aged
Multiple Myeloma / drug therapy*
Progression-Free Survival
Recurrence
Salvage Therapy*
Thalidomide / administration & dosage
Thalidomide / adverse effects

Substances

Thalidomide
Dexamethasone
Lenalidomide

Grants and funding